Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Methods for Determining Hepatocellular Carcinoma Subtype and Detecting Hepatic Cancer Stem Cells

Posted Jul 31 2007 5:00pm

Description of Invention:
Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide, and it is very heterogeneous in terms of its clinical presentation as well as genomic and transcriptomic patterns. HCC can originate from both adult hepatocytes and hepatic progenitor cells. The extent of progenitor cell activation and the direction of differentiation are correlated with the severity of the disease. HCC patient variability indicates that HCC comprises several biologically distinct subtypes. This heterogeneity and the lack of appropriate biomarkers have hampered patient prognosis and treatment stratification.

Available for licensing are microRNA biomarkers that are associated with four HCC subtypes: hepatic stem cell-like, bile duct epithelium-like, hepatocytic progenitor-like, and mature hepatocyte-like. One unique profile is associated with HCC with features of liver stem cells and poor patient prognosis. It has both diagnostic and therapeutic value in the management of HCC patients.

Applications:
  • A diagnostic assay where HCC treatment can be individualized according to patient HCC subtype
  • An assay for HCC to prognose patient survival
  • Therapeutic compositions that target subtype specific HCC


Development Status:
The technology is currently in the pre-clinical stage of development.

Inventors:
Xin Wei Wang (NCI)


Patent Status:
HHS, Reference No. E-215-2007/0
PCT, Application No. PCT/US2008/007196 filed 09 Jun 2008
US, Application No. 12/663,586 filed 21 Apr 2010


Relevant Publication:
  1. Presented at Keystone Symposia on MicroRNA and Cancer in June 2007.
  2. R Garzon et al. MicroRNA expression and function in cancer. Trends Mol Med. 2006 Dec;12(12):580-587. [ PubMed abs ]


Licensing Status:
Available for licensing.

Collaborative Research Opportunity:
The National Cancer Institute, Laboratory of Human Carcinogenesis, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.


Portfolios:
Cancer
Cancer - Diagnostics
Cancer - Therapeutics
Gene Based Therapies
Gene Based Therapies - Therapeutics



For Additional Information Please Contact:
Jennifer Wong
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: wongje@mail.nih.gov
Phone: 301-435-4633
Fax: 301-402-0220


Ref No: 1586

Updated: 08/2007

Post a comment
Write a comment:

Related Searches